No Data
No Data
Intellia Therapeutics' Promising Future: Buy Rating Backed by Strong Financials and Program Advancements
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $9 to $33
Express News | Citigroup Maintains Neutral on Intellia Therapeutics, Raises Price Target to $14
Intellia Therapeutics Price Target Cut to $68.00/Share From $91.00 by Chardan Capital
Intellia Therapeutics Is Maintained at Buy by Chardan Capital
Unlock the Full List
DD07 : is it still an entry position